

PIN Pharma to Present a Poster at AACR Inaugural International Cancer Immunotherapy Conference, Translating Science into Survival 2015

(New York, NY) September 14, 2015 – PIN Pharma, a pre-IND immunotherapy company focused on oncology, today announced the Company will be presenting a poster (B080) on Friday, September 18, 2015 from 4:45 pm – 6:45 pm entitled, PIN-2, A Novel Immunomodulatory Peptide.

About PIN Pharma, Inc.

PIN Pharma is a pre-IND stage venture backed immunotherapy company focused on the development of PINS (precision immune stimulants). The lead compound PIN-2 is a first-in-class, novel, next-generation engineered peptide that empowers the immune system *in vivo*. The Company's technology primes the innate immune system to modulate adaptive immunity thereby generating and expanding antigen-specific cytotoxic T-cells *in vivo*. Colin Bier, CEO and CSO of PIN Pharma indicated that, "I am very excited to be involved with the development of this novel and unique therapy. PINS have the potential to revolutionize the standard of care for treating cancer by rapidly enhancing and optimizing the patient's own immune response". The data supports advancing to clinical investigation of PINS.

Contact

For more information about PIN Pharma and PIN-2, contact Mark Smith, CBO (msmith@pinpharma.com) or Colin Bier, CEO (cbier@pinpharma.com) at PIN Pharma, Inc., 3960 Broadway, Suite 620, New York, NY, or call 212-543-2583.